Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health and Human Services
- Centers for Disease Control and Prevention
This publication has 18 references indexed in Scilit:
- Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United StatesNew England Journal of Medicine, 2023
- An Mpox-Related Death in the United StatesNew England Journal of Medicine, 2023
- Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational studyThe Lancet Infectious Diseases, 2023
- Mpox in people with advanced HIV infection: a global case seriesThe Lancet, 2023
- Real-world effectiveness of a single dose of mpox vaccine in malesNature Medicine, 2023
- Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022New England Journal of Medicine, 2022
- A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDSVaccine, 2020
- Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against SmallpoxNew England Journal of Medicine, 2019
- Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II TrialOpen Forum Infectious Diseases, 2015
- Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challengeVaccine, 2007